The optimized anti-CD20 monoclonal antibody ublituximab bypasses natural killer phenotypic features in Waldenstrom macroglobulinemia

被引：6

作者：

Le Garff-Tavernier, Magali ^{[1
,2
,3
]}

Herbi, Linda ^{[1
,2
,4
]}

de Romeuf, Christophe ^{[4
]}

Azar, Nabih ^{[5
]}

Roos-Weil, Damien ^{[1
,5
]}

Bonnemye, Patrick ^{[3
]}

Urbain, Remi ^{[4
]}

Leblond, Veronique ^{[1
,5
]}

Merle-Beral, Helene ^{[1
,3
,6
]}

Vieillard, Vincent ^{[1
,2
,7
]}

机构：

[1] Univ Paris 06, Sorbonne Univ, Paris, France

[2] CIMI Paris, U1135, INSERM, Paris, France

[3] Hop La Pitie Salpetriere, AP HP, Serv Hematol Biol, Paris, France

[4] Lab Francais Fractionnement & Biotechnol LFB, Les Ulis, France

[5] Hop La Pitie Salpetriere, AP HP, Serv Hematol Clin, Paris, France

[6] Ctr Rech Cordeliers, Team 19, INSERM, U1138,Programmed Cell Death & Physiopathol Tumor, Paris, France

[7] CIMI Paris, ERL8255, CNRS, Paris, France

来源：

HAEMATOLOGICA | 2015年 / 100卷 / 04期

关键词：

LYMPHOCYTIC-LEUKEMIA CELLS; NK CELLS; T-CELLS; EXPRESSION; THERAPY;

D O I：

10.3324/haematol.2014.118083

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：E147 / E151

页数：5

共 50 条

[1] Ublituximab, an Optimized Anti-CD20 Monoclonal Antibody, Demonstrates Greater NK-Mediated ADCC Than Rituximab in Waldenstrom's Macroglobulinemia Patients Supporting a Therapeutic Strategy with Ublituximab
Le Garff-Tavernier, Magali
Herbi, Linda
de Romeuf, Christophe
Prost, Jean-Francois
Debre, Patrice
Urbain, Remi
Leblond, Veronique
Vieillard, Vincent
Merle-Beral, Helene
[J]. BLOOD, 2012, 120 (21)
[2] Complete response to anti-CD20 monoclonal antibody in Waldenstrom's Macroglobulinemia after failure to purine analogs.
Colares, M
Lerner, D
de Lima, MG
Romano, S
Motta, I
Tabak, DG
[J]. BLOOD, 1999, 94 (10) : 259B - 259B
[3] Ublituximab, a Novel, Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), Demonstrates Enhanced Antibody-Dependent Cellular Cytotoxicity (ADCC) Relative to Other Anti-CD20 mAbs
Huang, Deren
Alvarez, Enrique
Miskin, Hari
Lee, Lily
Foley, John
[J]. NEUROLOGY, 2023, 100 (17)
[4] Antibody-dependent cellular cytotoxicity of the optimized anti-CD20 monoclonal antibody ublituximab on chronic lymphocytic leukemia cells with the 17p deletion
M Le Garff-Tavernier
L Herbi
C de Romeuf
F Nguyen-Khac
F Davi
A Grelier
M Boudjoghra
K Maloum
S Choquet
R Urbain
V Vieillard
H Merle-Béral
[J]. Leukemia, 2014, 28 : 230 - 233
[5] Antibody-dependent cellular cytotoxicity of the optimized anti-CD20 monoclonal antibody ublituximab on chronic lymphocytic leukemia cells with the 17p deletion
Le Garff-Tavernier, M.
Herbi, L.
de Romeuf, C.
Nguyen-Khac, F.
Davi, F.
Grelier, A.
Boudjoghra, M.
Maloum, K.
Choquet, S.
Urbain, R.
Vieillard, V.
Merle-Beral, H.
[J]. LEUKEMIA, 2014, 28 (01) : 230 - 233
[6] Ofatumumab, a human anti-CD20 monoclonal antibody
Osterborg, Anders
[J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2010, 10 (03) : 439 - 449
[7] Anti-CD20 monoclonal antibody in autoimmune diseases
Pogliani, EM
Larocca, A
[J]. BIOMEDICINE & PHARMACOTHERAPY, 2002, 56 (07) : 350 - 351
[8] Ofatumumab: a novel monoclonal anti-CD20 antibody
Lin, Thomas S.
[J]. PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2010, 3 : 51 - 59
[9] Anti-CD20 monoclonal antibody/thalidomideMyeloproliferative disorder in an elderly patient (first report with anti-CD20 monoclonal antibody): case report
[J]. Reactions Weekly, 2001, 855 (1) : 7 - 7
[10] Obinutuzumab: a new class of anti-CD20 monoclonal antibody
Gagez, Anne-Laure
Cartron, Guillaume
[J]. CURRENT OPINION IN ONCOLOGY, 2014, 26 (05) : 484 - 491

← 1 2 3 4 5 →